期刊文献+

围绝经期应用不同剂量绝经激素治疗的临床观察 被引量:8

Effects of different doses of menopause hormone therapies in perimenopausal women
原文传递
导出
摘要 目的比较不同剂量绝经激素治疗(MHT)对缓解患者绝经相关症状的有效性和安全性。方法回顾分析2012年至2017年就诊浙江大学医学院附属妇产科医院妇科内分泌门诊的围绝经期综合征患者450例,根据MHT方案中雌激素剂量分为3组,A组:标准剂量组(n=62),B组:低剂量组(n=322)及C组:超低剂量组(n=66)。以28 d为1个治疗周期,连续序贯给药。分别于治疗前后进行改良Kupperman问卷评分、生殖激素及糖脂代谢指标测定、乳腺超声检查。结果治疗前3组患者在一般资料及各临床观察指标上差异均无统计学意义(P均> 0.05)。与治疗前相比,治疗1、3、6个周期后,3组改良Kupperman评分、血清卵泡刺激素(FSH)均下降,雌二醇(E2)均上升,差异有统计学意义(P均<0. 001)。B组与C组高密度脂蛋白胆固醇在治疗6周期后均较治疗前升高,A组与B组低密度脂蛋白胆固醇在治疗6周期后均较治疗前下降,差异有统计学意义(P均<0. 01); A组与B组空腹血糖、空腹胰岛素在治疗6周期后均较治疗前下降,差异有统计学意义(P均<0. 01)。治疗前后3组乳腺腺体厚度、结节大小、导管扩张程度均无明显变化(P均> 0. 05); A组7例(11. 3%)、B组14例(4. 3%)、C组1例(1. 5%)出现乳房胀痛,发生率在A、C组间差异有统计学意义(P <0. 05)。结论标准剂量、低剂量、超低剂量MHT均有效缓解围绝经期患者的绝经症状。其中,标准剂量、低剂量MHT在改善糖脂代谢方面优于超低剂量MHT,超低剂量MHT在耐受方面具有一定优势,观察期内不同剂量MHT均对乳腺无影响。 Objective To compare the effectiveness and safety of different doses of menopause hormone therapies(MHT)in the remission of menopausal symptoms.Methods The clinical data of 450 perimenopausal women who received MHT during 2012 and 2017 were retrospectively analyzed.According to the doses of estradiol valerate,the patients were divided into 3 groups:group A(standard dose,n=62),group B(low dose,n=322)and group C(ultralow dose,n=66).One treatment cycle lasted for 28 days,during which the continuous sequential regimen was adopted.Before and after treatment,modified Kupperman menopausal index(mKMI)were surveyed,reproductive hormones and glucolipid metabolic indexes were detected,and breast ultrasound was performed.Results Before treatment,there were no significant differences in the general characters and clinical indexes among the 3 groups(all P>0.05).Compared to baseline,the mKMI scores and follicle stimulating hormone(FSH)level significantly decreased,while estradiol level significantly increased after 1,3 and 6 treatment cycles in all 3 groups(all P<0.001).After 6 treatment cycles,the level of high-density lipoprotein cholesterol(HDL-C)markedly increased in groups B and C,and the levels of low-density lipoprotein cholesterol(LDL-C),fasting blood glucose and fasting insulin significantly decreased in groups A and B(all P<0.01).There were no statistical changes in the thickness of mammary glands,size of mammary nodules and dilatation of ducts in the 3 groups before and after treatment(all P>0.05).Breast distention occurred in 7 cases(11.3%)in group A,14 cases in group B(4.3%)and 1 case in group C(1.5%),the difference in incidence between groups A and C was significant(P<0.05).Conclusion The standard,low and ultra-low doses of MHT can effectively relieve the menopausal symptoms in perimenopausal women.The standard and low dose are superior to the ultra-low dose in improving glucolipid metabolism.The ultra-low dose has advantages in tolerance.The different doses of MHT has no effects on the mammary glands during the observation period.
作者 徐文娴 王泉梅 马麟娟 黄艺舟 戚彤云 傅东霞 宋阳 兰义兵 李春明 陈沛琼 应倩 周坚红 XU Wenxian;WANG Quanmei;MA Linjuan;HUANG Yizhou;QI Tongyun;FU Dongxia;SONG Yang;LAN Yibing;LI Chunming;CHEN Peiqiong;YING Qian;ZHOU Jianhong(Department of Gynecology,Women’s Hospital,School of Medicine,Zhejiang University,Hangzhou 310006,Zhejiang,China;Department of Obstetrics and Gynecology,The First People’s Hospital of Tonglu,Tonglu 311500,Zhejiang,China;Journal of Chinese Oncology,Zhejiang Cancer Hospital,Hangzhou 310022,Zhejiang,China)
出处 《山东大学学报(医学版)》 CAS 北大核心 2019年第2期44-51,共8页 Journal of Shandong University:Health Sciences
基金 国家自然科学基金(81873810) 浙江省教育厅面上项目(Y201534797) 浙江省教育厅一般项目(Y201738349) 浙江省医药卫生科技计划项目(2018KY435)
关键词 绝经激素治疗 围绝经期 低剂量 超低剂量 绝经相关症状 Menopause hormone therapy Perimenopause period Low dose Ultra-low dose Menopausal symptoms
  • 相关文献

参考文献5

二级参考文献63

  • 1魏向群,张鸿慧,魏振华,白庭富,钱贵生.新平县彝族傣族妇女绝经年龄及相关情况调查[J].云南医药,2004,25(4):280-282. 被引量:4
  • 2徐秦,任淑珍,尔西丁,艾赛提,徐兰,郭丽丽,扎依达,丁红.乌鲁木齐市维吾尔族与汉族妇女绝经年龄及影响因素[J].中华预防医学杂志,1995,29(6):322-322. 被引量:4
  • 3闫凤亭,李大金.绝经后激素治疗现状[J].中国妇幼健康研究,2006,17(1):51-53. 被引量:2
  • 4中华医学会妇产科学分会绝经学组.绝经过渡期和绝经后激素补充治疗临床应用指南.中华妇产科杂志,2010,45(7):635-637.
  • 5Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women 's Health Initiative randomized controlled trial[ J]. JAMA,2002, 288:321-333.
  • 6Van deWeijer PH, Mattsson LA, Ylikorkala O. Benefits and risks of long-term low-dose oral continuous combined hormone therapy[ J]. Maturitas, 2007,56(3 ):231-248.
  • 7Ettinger B. Rationale for use of lower estrogen doses for postmenopausal hormone therapy[ J]. Maturitas ,2007,57 ( 1 ) :81-84.
  • 8Langer RD. Efficacy, safety, and tolerability of low-dose hormone therapy in managing menopausal symptoms [ J ]. J Am Board Fam Med ,2009,22 ( 5 ) :563-573.
  • 9Rozenbaum H. How to evaluate the risk-benefit ratio of the lowdose hormone replacement therapy? [ J ]. J Steroid Biochem Mol Biol,2006,102( 1-5 ) :256-260.
  • 10Board of the International Menopause Society, Pines A, Sturdee DW, et al. Updated recommendations on postmenopausal hormone therapy[ J]. Climacteric ,2007,10( 3 ) : 181-194.

共引文献215

同被引文献81

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部